Access
To read this story in full you will need to login or make a payment (see right).
Commentary
Nature 448, 645-646 (9 August 2007) | doi:10.1038/448645a; Published online 8 August 2007
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Postdoctoral Position Studying Immunology
- The University of Chicago
- Chicago, IL
Tenure-Track Faculty Positions
- The University of Texas Southwestern Medical Center
- Dallas, TX 75390-9148 United States
New uses for old drugs
Curtis R. Chong1 & David J. Sullivan, Jr2
- Curtis R. Chong is in the Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
- David J. Sullivan Jr is at the Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA.
Abstract
It takes too long and costs too much to bring new drugs to market. So let's beef up efforts to screen existing drugs for new uses, argue Curtis R. Chong and David J. Sullivan Jr.
Fast, affordable drug development is a vision that contrasts sharply with the current state of drug discovery — which also neglects too many diseases of the poor. An analysis1 of 68 approved drugs estimated that it takes an average of 15 years and US$800 million to bring a single drug to market.
To read this story in full you will need to login or make a payment (see right).
